| HOME >> BIOLOGY >> TECHNOLOGY |
) (2,949)
Other income (expense):
Interest expense (570) (435)
Other, net 15 (151)
Loss before income taxes (569) (3,535)
Income tax (benefit) expense (74) 42
Net loss $(495) $(3,577)
Net loss per common share - assuming dilution $(0.33) $(2.81)
Weighted average shares outstanding -
assuming dilution 1,486.9 1,273.7
BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET (LOSS) INCOME AND NET (LOSS) INCOME PER COMMON SHARE
RECONCILIATIONS
(Unaudited)
An explanation of the ways in which Boston Scientific management uses
these non-GAAP measures to evaluate its business, the substance behind
Boston Scientific management's decision to use these non-GAAP measures,
the material limitations associated with the use of these non-GAAP
measures, the manner in which Boston Scientific management compensates for
those limitations, and the substantive reasons why Boston Scientific
management believes that these non-GAAP measures provide useful
information to investors is included in the exhibit labeled "Use of Non-
GAAP Financial Measures.
Year Ended Year Ended
December 31, 2007 December 31, 2006
Impact per Impact per
In millions, except per Net income diluted Net income diluted
share data (loss) share (loss) share
GAAP results $(495) $(0.33) $(3,577) $(2.81)
N
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Boston Scientific to Participate in Merrill Lynch Conference
2. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
5. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
6. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
7. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
8. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
9. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
10. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
11. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |